Cambridge, UK; 15th July, 2020. 

Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”) and AcedrA Pharmaceutical Company (“AcedrA”) are delighted to announce the signing of a Memorandum of Understanding (MOU); to explore a partnership and commercialization by AcedrA of Atlantic Healthcare’s products into the Middle East and Africa.

Atlantic Healthcare is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.  The Company plans to partner with established pharmaceutical companies to commercialize its products in the rest of the world, including the Middle East.

AcedrA is a respected, ambitious, high-growth pharmaceutical company with a strong reputation amongst the hospital and healthcare community across the Middle East and Africa.

Atlantic Healthcare is currently developing alicaforsen, a novel antisense drug in development for treatment of ulcerative colitis and Crohn’s disease. Its lead programme for ulcerative colitis is being prepared for a Phase 3 clinical trial, which if successful, can be the basis for filing for regulatory approvals.

The Company is also developing renzapride for the treatment of gastro-intestinal motility diseases including the effects on the GI tract of rare diseases systemic scleroderma, cystic fibrosis, and Parkinson’s Gastroparesis.

Dr Hosni Sta, CEO of AcedrA said: “We are honoured by this agreement which will further focus the role of AcedrA in promoting R&D. Atlantic Healthcare is a prime example of innovation serving patients where medical needs are unmet.”

Mr. Mesfer Al Dosari, Chairman of the Board said: “I hope that this memorandum of understanding between Atlantic Healthcare and AcedrA will let both companies explore the best options in the META region for the benefits of patients and scientific communities.”

Toby Wilson Waterworth, CEO of Atlantic Healthcare said: “I’m delighted to be able to announce this memorandum of understanding to explore partnership with AcedrA to commercialize Atlantic Healthcare products in the Middle Eastern region.“

About Atlantic Healthcare
Atlantic Healthcare plc (https://www.atlantichc.com/) is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing agreements with established pharmaceutical companies in the rest of the world.

For more information about Atlantic Healthcare, alicaforsen or renzapride, please contact:

Adam Michael (Head of Communications)
+44 1799 512 055
+44 777 588 1813
adam.michael@atlantichc.com

About AcredrA Pharmaceutical Company
AcedrA BioPharmaceuticals (http://acedrarx.com), specializes in registering, accessing, distributing, promoting and marketing Pharmaceutical, Medical Devices & Biotechnology products in the Middle East and Africa. The Company has been recognised as one of the Top 50 healthcare companies for its contribution to the pharmaceutical ecosystem in the Middle East.

AcedrA is is fully integrated business and scientific services company providing access to the best available therapies for unmet commercial and medical needs.

For more information about AcedrA Pharmaceutical Company, please contact:

Layla Wahabi (Chief Compliance Officer)
+966 11 400 00 32
+966 56 161 81 76
Layla.wah@acedrarx.com